The Company’s product pipeline has more than 30 programs of 12 drugs This product pipeline mainly focuses on the treatment of solid and hematologic cancers, bleeding and blood diseases, liver and gallbladder diseases, and inflammatory-immune diseases, and is also expanding to include other diseases.
The Company is continually improving its R&D technology platforms to optimize and develop its pipeline through in-house R&D and external cooperation and prioritizing attention to product advancement, differentiation and commercialization in these fields. Current clinical testing of the combination of its targeted small molecule drugs, including Donafenib, with immunotherapy antibody drugs like anti-PD-1/PD-L1 antibodies. Expanding upon this experience, the Company is developing new generation of immunotherapeutic antibody drugs. Additionally, novel drugs for hepatobiliary precancerous lesions, including non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis (PBC) and other diseases that no effective medicines are available are being developed that will strengthen our competitive position in the hepatobiliary treatment field, and capitalize on the opportunity in this large market. In addition, the company is developing a number of blood hemostasis products applicable to multiple hemorrhage conditions. Beyond building a robust pipeline, the Company is also establishing a wide range of partnerships both in China and abroad that will greatly increase the geographical opportunities for our business.
The Company's drugs currently in research and development are shown below: